3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $28.4B | $1.16T | 26.4% | 7.8% | $1.3B | $12.6B | $1.9B |
| 2024 | $25.5B | — | 27.3% | 8.4% | $1.4B | $16.5B | $199M |
| 2023 | $23.2B | — | 25.3% | 5.4% | $1.4B | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $7.4B | $239M | 25.0% | 5.7% | $316M | $12.6B | $2.2B |
| Mar '25 | $6.6B | — | 27.5% | 8.6% | $584M | — | — |
How the market has priced MDLN against its own fundamentals since 2025-12 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Medline Inc.'s revenue has grown 10.6% per year. These are computed facts, not advice.
As of FY2025, Medline Inc. reported $12.6B of total debt against $1.9B of cash; operating income covered interest expense 2.3×.
In FY2025, gross margin was 26.4%, operating margin 7.8%, and net margin 4069.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.